Aurantiamide 是一种非共价、口服有效且可透过血脑屏障的 GRPR 选择性拮抗剂,具有抗炎活性和神经保护作用,它通过抑制 GRPR 介导的肾坏死通路(如 RIPK3/MLKL 信号)和 NF-κB 炎症通路来减轻肾组织炎症和氧化应激,从而发挥抗急性肾损伤和改善内皮功能的活性,同时还通过抑制小胶质细胞 M1 型极化和 NLRP3 激活来改善 AD 小鼠模型,并在缺血/再灌注、脓毒症等急性肾损伤模型及高血压模型中均具有体内抑制效力。
产品编号: MS-P64574 纯度: 99.56% CAS No.: 58115-31-4 分子式: C25H26N2O3 分子量: 402.49
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Aurantiamide 是一种非共价、口服有效且可透过血脑屏障的 GRPR 选择性拮抗剂,具有抗炎活性和神经保护作用,它通过抑制 GRPR 介导的肾坏死通路(如 RIPK3/MLKL 信号)和 NF-κB 炎症通路来减轻肾组织炎症和氧化应激,从而发挥抗急性肾损伤和改善内皮功能的活性,同时还通过抑制小胶质细胞 M1 型极化和 NLRP3 激活来改善 AD 小鼠模型,并在缺血/再灌注、脓毒症等急性肾损伤模型及高血压模型中均具有体内抑制效力。

生物实验数据

生物活性 Aurantiamide is a non-covalent, orally active, blood-brain barrier-permeable GRPR-selective antagonist with anti-inflammatory activity and neuroprotective effects that alleviates renal tissue inflammation and oxidative stress by inhibiting GRPR-mediated renal necrotic pathways (such as RIPK3/MLKL signaling) and the NF-κB inflammatory pathway, thereby exerting anti-acute kidney injury and endothelial function-improving activities, while also ameliorating AD mouse models by inhibiting M1 polarization of microglia and NLRP3 activation, and exhibiting in vivo inhibitory efficacy in acute kidney injury models such as ischemia/reperfusion and sepsis as well as in hypertension models.
IC50 & Target

NF-κB

 

RIPK3

 

体外研究
(In Vitro)

Aurantiamide (25、50、100 μM;12 h) 在人肾近端小管上皮细胞 (HK-2)缺氧/复氧及 LPS (1 mg/mL) 刺激模型中,显著降低肾损伤标志物 KIM1 的蛋白及 mRNA 表达,抑制 RIPK3/MLKL 坏死通路及 NF-κB 炎症通路相关蛋白磷酸化,减轻细胞损伤与炎症反应。
Aurantiamide (10,20 μM;24 h) 在小鼠 BV2 细胞中,抑制 LPS 和 IFN-γ 诱导的 BV2 活化和 M1 型极化,抑制 NLRP3 的激活,从而发挥抗中枢神经炎症的活性。
Aurantiamide 促进小胶质细胞发生 M2 极化改善阿尔茨海默病小鼠认知能力。
Aurantiamide (3 μM;18 h) 在人脐静脉内皮细胞 (HUVEC) 中,显著上调内皮型一氧化氮合酶 (eNOS) 的 mRNA 和蛋白表达,促进一氧化氮 (NO) 生成,且对细胞活力无显著毒性影响。

Western Blot Analysis

Cell Line: Human proximal tubule epithelial cells (HK-2) [LPS-induced model]
Concentration: 25 μM, 50 μM, 100 μM
Incubation Time: 24 h
Result: WB (Western blot): Reduced protein expression of renal injury marker KIM1, phosphorylated RIPK3 (p-RIPK3), phosphorylated MLKL (p-MLKL), and phosphorylated P65 (p-P65) in a dose-dependent manner, compared to H/R or LPS-stimulated controls.
qPCR: Downregulated mRNA levels of KIM1, MCP-1, and IL-6, with significant inhibition at 50 μM and 100 μM.
IF (Immunofluorescence): Decreased immunofluorescent intensity of p-MLKL and KIM1 in cytoplasm, indicating reduced necroptosis and tubular injury.

Western Blot Analysis

Cell Line: Human umbilical vein endothelial cells (HUVEC)
Concentration: 3 μM
Incubation Time: 18 h
Result: No significant cytotoxicity observed, with cell viability maintaining over 90% compared to control.
WB (Western blot): Upregulated eNOS protein expression by 1.8-fold compared to control, with enhanced NO production detected by nitrite/nitrate assay.
\qPCR: Increased eNOS mRNA expression by 2.3-fold, confirming transcriptional activation of eNOS.
体内研究
(In Vivo)

Aurantiamide (2.5、5、10 mg/kg;口服灌胃;共 3 次,每次间隔 24 h) 在 C57BL/6 小鼠缺血/再灌注 (I/R) 和盲肠结扎穿刺 (CLP) 呈剂量依赖性改善 AD 小鼠的认知障碍,并抑制小胶质细胞的极化和 NLRP3 的激活。
Aurantiamide (0.5 mg/kg;腹腔注射;每日一次,每周 5 天;4 周) 在 Sprague-Dawley 大鼠两肾一夹 (2K-1C) 肾血管性高血压模型中,显著降低平均动脉血压,改善内皮依赖性血管舒张功能,上调主动脉内皮型一氧化氮合酶 (eNOS) 蛋白表达并促进一氧化氮 (NO) 生成。
Aurantiamide (0.1 mg/kg;灌胃;单剂量) 与 Aurantiamide acetate (MS-H42619) (0.2 mg/kg;灌胃;单剂量) 在大鼠中的代谢特征显示,其具有扩散快,分布广泛,可透过血脑屏障的特点,达峰时间为 0.5 h。并且,Aurantiamide acetate 的下降速度比 Aurantiamide 更快。

Animal Model: Male C57BL/6 mice (6-8 weeks old, 20-22 g) + cisplatin-induced, I/R, or CLP-induced acute kidney injury model
Dosage: 2.5, 5, 10 mg/kg (dissolved in 0.5% carboxymethylcellulose + 0.1% Tween 80)
Administration: Oral gavage, three times before the surgery, with a 24 h interval between each administration
Result: Renal function: Reduced serum creatinine and BUN levels by 30-45% compared to model controls, with the 10 mg/kg dose showing the most pronounced effect.
Histopathology: PAS staining revealed decreased tubular dilation, glycogen deposition, and interstitial fibrosis; immunofluorescence showed reduced KIM1 (renal injury marker) and F4/80+ macrophage infiltration in renal tissues.
Protein expression: Western blot demonstrated dose-dependent inhibition of p-RIPK3, p-MLKL, and p-P65 (NF-κB) in renal lysates, with corresponding reduction in pro-inflammatory cytokines (IL-6, TNF-α) by qPCR.
Animal Model: Male Sprague-Dawley rats (8 weeks old, 230-250 g) + two-kidney one-clip (2K-1C) renovascular hypertension model
Dosage: 0.5 mg/kg (dissolved in DMSO, final concentration 0.1%)
Administration: Intraperitoneal injection, once daily for 5 days/week, total 4 weeks
Result: Blood pressure: Reduced mean arterial pressure (MAP) by 20-25% compared to hypertensive controls, with significant improvement in endothelium-dependent relaxation to acetylcholine (ACh) and reduced constriction to phenylephrine (Phe).
Vascular function: Organ bath assays showed enhanced ACh-induced vasodilation and attenuated Phe-induced vasoconstriction in aortic rings, correlated with increased eNOS protein expression (1.5-fold by Western blot) and NO production (measured as nitrite/nitrate levels).
Red blood cell deformability: Ektacytometry revealed increased erythrocyte deformability (Elmax) in treated rats, indicating improved blood fluidity and microvascular flow.
性状 固体
颜色 White to off-white

化学信息

分子量 402.49
分子式 C25H26N2O3
CAS No. 58115-31-4

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (8.2 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

-20°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (124.23 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.4845 mL12.4227 mL24.8453 mL62.1133 mL
5 mM0.4969 mL2.4845 mL4.9691 mL12.4227 mL
10 mM0.2485 mL1.2423 mL2.4845 mL6.2113 mL
15 mM0.1656 mL0.8282 mL1.6564 mL4.1409 mL
20 mM0.1242 mL0.6211 mL1.2423 mL3.1057 mL
25 mM0.0994 mL0.4969 mL0.9938 mL2.4845 mL
30 mM0.0828 mL0.4141 mL0.8282 mL2.0704 mL
40 mM0.0621 mL0.3106 mL0.6211 mL1.5528 mL
50 mM0.0497 mL0.2485 mL0.4969 mL1.2423 mL
60 mM0.0414 mL0.2070 mL0.4141 mL1.0352 mL
80 mM0.0311 mL0.1553 mL0.3106 mL0.7764 mL
100 mM0.0248 mL0.1242 mL0.2485 mL0.6211 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础